Brief: PMV Pharmaceuticals Updates PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With TP53 Y220C Mutation
12/10/2023 17:36
Oct 12 (Reuters) - PMV Pharmaceuticals Inc PMVP.O :
* PMV PHARMACEUTICALS UPDATED PC14586 PHASE 1 DATA
DEMONSTRATED
ANTI-TUMOR ACTIVITY ACROSS MULTIPLE SOLID TUMOR TYPES WITH A
TP53 Y220C MUTATION
* PMV PHARMACEUTICALS INC - PLANS TO INITIATE A
REGISTRATIONAL
PHASE 2 TRIAL IN EARLY 2024
* PMV PHARMACEUTICALS - UPDATED PHASE 1 RESULTS FROM ITS
ONGOING
PHASE 1/2 PYNNACLE CLINICAL TRIAL WAS WELL TOLERATED WITH A
FAVORABLE SAFETY PROFILE
Source text for Eikon: ID:nGNX9Z4BqS
Further company coverage: PMVP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pmv Pharmaceuticals
See all newsAustralia's Premier Investments jumps as Citi backs in-line earnings
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics